TScan slashes 75% of staff

TScan Therapeutics is making one of the sharper pivots now showing up across cell therapy. On September 2, the company said it will cut roughly 75% of its workforce, pause parts of its hematology and autoimmune work, and redirect research spending toward in vivo-engineered TCR-T programs for solid tumors. (ir.tscan.com) The reorganization is tied directly to capital: TScan said the move should preserve cash into the fourth quarter of 2027. ### Why is TScan cutting so deeply? (stocktitan.net) The company’s September 2 announcement linked the layoffs to a broader restructuring of its pipeline. TScan said it is pausing further enrollment in the Phase 3 ALLOHA-2 study of TSC-101 because it does not have enough capital to continue as planned, while it lets existing data mature and looks for collaboration partners. (ir.tscan.com) The 8-K filed for an event dated August 27 put numbers around the decision. TScan said the reorganization and workforce reduction are expected to deliver about $55 million in cumulative cost savings through the end of 2027. (ir.tscan.com) ### What is the company choosing to keep? TScan said the center of gravity is now its in vivo cell therapy work in solid tumors. Specifically, the company said it is advancing two in vivo-engineered TCR-T candidates into IND-enabling studies, with plans to begin Phase 1 development in the fourth quarter of 2027. The same update paired that shift with fresh data from Cohort C of the Phase 1 ALLOHA study. (ir.tscan.com) TScan said 100% of the 13 patients currently being tracked showed complete donor chimerism, even as it moved to halt new enrollment in ALLOHA-2. ### What does this say about TScan’s older programs? (stocktitan.net) The company’s own language makes the trade-off clear. TScan said the workforce reduction follows the pause of its hematological and autoimmune programs as it prioritizes preclinical in vivo solid-tumor programs. Fierce Biotech described the move the same way in its layoff tracker and separate report on the restructuring. (ir.tscan.com) That leaves TScan trying to move from a broader platform story to a narrower one built around fewer assets and a longer cash runway. The company said it is also actively seeking collaboration partners for the paused Phase 3 program. (ir.tscan.com) ### Is TScan an outlier in cell therapy right now? ArsenalBio and Cellares show the pressure is wider than one company. ArsenalBio cut 99 jobs on August 31 and said it was refocusing on in vivo CAR-T therapy while stopping development of ex vivo clinical assets, according to layoff tracking and industry reports. Cellares, meanwhile, has been cutting staff after Bristol Myers Squibb ended a manufacturing partnership tied to Breyanzi. (fiercebiotech.com) BioSpace reported Cellares planned to lay off about 100 people, while Reuters reported Bristol Myers ended the partnership after concluding Cellares’ system could not meet requirements for producing the therapy. (ir.tscan.com) ### What should investors and employees watch next? September 2 was also the date TScan scheduled a webcast to discuss the restructuring at 8:30 a.m. ET. The company’s next concrete markers are operational rather than commercial: IND-enabling work on the two solid-tumor candidates, any collaboration update on ALLOHA-2, and the planned Phase 1 start in Q4 2027. (ir.tscan.com) (biospace.com) (layoffhedge.com)